4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective δ-opioid agonists
摘要:
A novel series of 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives has been prepared and their synthesis described herein. In vitro affinities for delta-, mu-, and kappa-opioid receptors, as well as the functional activity in the [S-35]GTP gamma S assay are reported. The most potent and selective delta-opioid agonist 18a exhibited a K-i of 18 nM, and was > 258-fold and 28-fold selective over mu- and kappa-receptors, respectively; the compound is a full agonist with an EC50 value of 14 nM. (c) 2005 Elsevier Ltd. All rights reserved.
4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective δ-opioid agonists
摘要:
A novel series of 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives has been prepared and their synthesis described herein. In vitro affinities for delta-, mu-, and kappa-opioid receptors, as well as the functional activity in the [S-35]GTP gamma S assay are reported. The most potent and selective delta-opioid agonist 18a exhibited a K-i of 18 nM, and was > 258-fold and 28-fold selective over mu- and kappa-receptors, respectively; the compound is a full agonist with an EC50 value of 14 nM. (c) 2005 Elsevier Ltd. All rights reserved.
4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives as non-peptidic selective δ-opioid agonists with potential anxiolytic/antidepressant properties. Part 2
作者:Andrés A. Trabanco、Nancy Aerts、Rosa M. Alvarez、José I. Andrés、Inge Boeckx、Javier Fernández、Antonio Gómez、Frans E. Janssens、Joseph E. Leenaerts、Ana I. De Lucas、Encarna Matesanz、Thomas Steckler、Shirley Pullan
DOI:10.1016/j.bmcl.2007.05.012
日期:2007.7
Novel 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives have been prepared and their synthesis described herein. In vitro affinities for delta-, mu-, and kappa-opioid receptors are reported. Evaluation of some representative compounds from this series in the mouse neonatal ultrasonic vocalization test and the mouse tail suspension test revealed anxiolytic- and antidepressant-like effects, respectively, upon subcutaneous administration. (C) 2007 Elsevier Ltd. All rights reserved.